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In healthy individuals, infections of the central nervous system (CNS) are comparatively rare.
Based on the ability of microglial cells to phagocytose and kill pathogens and on clinical
ﬁndings in immunocompromised patients with CNS infections, we hypothesize that an
intact microglial function is crucial to protect the brain from infections. Phagocytosis of
pathogens by microglial cells can be stimulated by agonists of receptors of the innate
immune system. Enhancing this pathway to increase the resistance of the brain to
infections entails the risk of inducing collateral damage to the nervous tissue.The diversity
of microglial cells opens avenue to selectively stimulate sub-populations responsible for
the defence against pathogens without stimulating sub-populations which are responsible
for collateral damage to the nervous tissue. Palmitoylethanolamide (PEA), an endogenous
lipid, increased phagocytosis of bacteria by microglial cells in vitro without a measurable
proinﬂammatory effect. It was tested clinically apparently without severe side effects.
Glatiramer acetate increased phagocytosis of latex beads by microglia and monocytes, and
dimethyl fumarate enhanced elimination of human immunodeﬁciency virus from infected
macrophages without inducing a release of proinﬂammatory compounds. Therefore, the
discovery of compounds which stimulate the elimination of pathogens without collateral
damage of neuronal structures appears an achievable goal. PEA and, with limitations,
glatiramer acetate and dimethyl fumarate appear promising candidates.
Keywords: microglia, blood–brain barrier, blood–CSF barrier, innate immune system, bacteria, phagocytosis,
palmitoylethanolamide
INTRODUCTION
In healthy young and middle-aged individuals beyond the neona-
tal period, infections of the central nervous system (CNS) are
rare events. Although the blood–brain and blood–cerebrospinal
ﬂuid (CSF) barriers, i.e., the endothelium of the vessels situ-
ated in the brain parenchyma and the epithelium of the choroid
plexuses, strongly impede the entry of pathogens into the CNS,
it probably is not uncommon that pathogens reach the brain tis-
sue or the CSF. In the CSF space, meningeal and perivascular and
few circulating macrophages can eliminate pathogens (Engelhardt
and Coisne, 2011). Moreover, pathogens can be transported by
the CSF bulk ﬂow (in humans approx. 20 ml/h) either through
the arachnoid granulations into the blood or along cranial and
spinal nerve roots into regional lymph nodes (Davson et al., 1987).
Meningeal macrophages and the glia limitans, composed of astro-
cytic foot processes and a parenchymal basement membrane,
impede the spread of pathogens from the CSF space into the brain
tissue.
Bacteria can cross the blood–brain and blood–CSF barrier
by (a) destruction of the endothelial cell layers (e.g., by pneu-
mococcal pneumolysin), (b) traversal in between the cells of
the barriers by disruption of the tight junctions, and (c) tran-
scytosis, an intracellular transport route designed to transport
molecules and vesicles through cells from the apical to basolateral
side (Tenenbaum et al., 2009; Iovino et al., 2013). The adhesion
of Escherichia coli, which reaches the brain by transcytosis, to
membrane receptors of the cerebrovascular endothelium triggers
a cascade of host cell signal transduction pathways resulting in
host cell actin cytoskeleton rearrangements. This process involves
host actin binding proteins and signaling molecules (e.g., Rac-
1) and microbial determinants (e.g., IbeA and OmpA; Maruvada
and Kim, 2012). Streptococcus pneumoniae preferentially adheres
to the subarachnoid vessels, and only at the later stages of infection
interacts with the endothelium of the choroid plexus (Iovino et al.,
2013).
We hypothesize that the entry of a pathogen into the CNS prob-
ably is not uncommon. Yet, in an immunocompetent host the vast
majority of pathogens, which eventually reach the brain tissue, are
either eliminated or controlled in a latent form by the immune
cells of the brain parenchyma, in particular, the microglial cells.
The immune defense of the CNS has been compared with
a medieval castle. The blood–brain and blood–CSF barriers
serve as the outer walls of the castle. The castle moat is rep-
resented by the CSF space. The second wall is represented by
the glia limitans and resident macrophages. Inside the castle,
i.e., the CNS parenchyma, “the royal family of sensitive neu-
rons resides” protected by (micro)glial cells (Engelhardt and
Coisne, 2011). Evidence for protective and reparative functions
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of microglial cells in the CNS has been found in diverse
neurologic diseases, particularly in Alzheimer’s disease, stroke
and excitotoxic brain injury (Anrather et al., 2011; Naert and
Rivest, 2011; Woo et al., 2012). The beneﬁcial aspects of the
immune response in the nervous system are beginning to be
appreciated and their potential as pharmacologic targets in
neurologic disease is being explored (Graber and Dhib-Jalbut,
2009). In a mouse model of Alzheimer’s disease, repeated sys-
temic injections of monophosphoryl lipid A, a LPS-derived
Toll-like receptor 4 (TLR4) agonist that exhibits immunomod-
ulatory properties at non-pyrogenic doses induced a potent
phagocytic response by microglia, reduced the amyloidβ load
in the brain and enhanced cognitive function (Michaud et al.,
2013).
The density of microglial cells in brain tissue depends on the
brain region. The healthy mouse brain contains an average of
approximately 7000 cells/μl, i.e., the same order of magnitude
as the density of leukocytes in the blood (calculated from Law-
son et al., 1990 assuming a volume of the adult mouse brain of
0.5 ml). Microglia are the most abundant immune cells of the
CNS. In their “resting” state, they continuously survey their envi-
ronment with highly mobile processes (Nimmerjahn et al., 2005;
Raivich, 2005). “Microglia are not notorious miscreants lurking
in the CNS to harm neurons on any occasion. They are not
placed there simply as a risk factor” (Hanisch, 2013). We are
convinced that they are the key players to eliminate or at least
control the replication of pathogens, which have entered the brain
and spinal cord despite the fortiﬁcations surrounding the nervous
tissue.
Statement: in healthy individuals, the protection of the CNS
against infections relies both on the integrity of the blood–CSF
and blood–brain barrier and on resident phagocytes, in particular
microglial cells and perivascular and meningeal macrophages.
PATHOPHYSIOLOGICAL ASPECTS OF ACUTE OR CHRONIC
CNS INFECTIONS
Bacterial meningitis, meningoencephalitis, and brain abscess are
life-threatening diseases with a high incidence in neonates, infants
and in the immunocompromised and elderly. Besides classical
pathogens (S. pneumoniae, Neisseria meningitides, Haemophilus
inﬂuenzae) the causative agents of CNS infections in persons
with an impaired immune system are other bacteria includ-
ing Gram-negative aerobic rods, group B streptococci, Nocardia
spp. and Listeria monocytogenes (Bouadma et al., 2006; Cabel-
los et al., 2008, 2009; Gaschignard et al., 2011; Lubart et al.,
2011). Immunocompromised patients also are susceptible to
meningitis and encephalitis caused by a variety of fungi, most fre-
quently Cryptococcus neoformans in AIDS patients and Aspergillus
spp. in patients on glucocorticoids and/or immunosuppres-
sants. In bacterial and fungal meningitis, pathogens proba-
bly frequently cross the choroid plexus (i.e., the blood–CSF
barrier; Tenenbaum et al., 2009), whereas in encephalitis and
brain abscess, they often cross the cerebrovascular endothelium
(i.e., the blood–brain barrier). In meningitis, encephalitis, and
brain abscess, the causative pathogens also can enter the brain
through a skull defect or along (thrombosed) vessels crossing the
skull.
Many viruses have a propensity to cause latent infections
and persist in cells of the central or peripheral nervous sys-
tem. The majority of these viruses belong to the family of
Herpesviridae (Traylen et al., 2011): herpes simplex virus (HSV)-
1, HSV-2, varicella zoster virus (VZV), Epstein–Barr virus (EBV),
cytomegalovirus (CMV),humanherpesvirus (HHV)-6 andHHV-
7. VZV, the most frequent viral cause of a reactivated infection
of the nervous system (Herpes zoster, encephalitis, meningitis,
myelitis, vasculitis), principally persists in neurons, and only
occasionally in other cells of the CNS (Cohen, 2007). Whereas
the incidence of HSV-1 encephalitis apparently is not increased
in the immunocompromised host, the strongest risk factor for
the development of VZV reactivation is age because of the age-
related natural decline in cellular immunity to VZV. Furthermore,
VZV, CMV, HSV-2, and HHV-6 and -7 typically cause reactivated
infections in immunosuppressed individuals.
Despite antiretroviral therapy (ART), HIV infection is respon-
sible for cognitive dysfunction and neurodegeneration through
persistent viral replication in the CNS, inﬂammation and
release of neurotoxic compounds from infected and/or activated
macrophages/microglia (Cross et al., 2011). Because of the poor
penetration of many antiretroviral drugs across the blood–brain
and blood–CSF barrier, the CNS frequently is a site of continued
HIV replication even when the viral load in blood is below the
detection limit (Letendre et al., 2008; Nau et al., 2010; van Lelyveld
et al., 2010).
Of the family of Polyomaviridae, JC virus causes progres-
sive multifocal leukencephalitis (PML). The incidence of PML
is <0.3 per 100,000 persons/year in the general population. In
persons with an immune defect, either by an underlying dis-
ease or by the administration of monoclonal antibodies such
as natalizumab, rituximab, efalizumab, and inﬂiximab, or other
immunosuppressants in the treatment of autoimmune or malig-
nant disease the incidence is increased (Bellizzi et al., 2013)
to 2.4 cases per 1000 persons/year in HIV-infected individuals
without combination antiretroviral therapy (cART) and to 2.1
cases per 1000 patients/year in multiple sclerosis (MS) patients
treated with natalizumab (Hirsch et al., 2013). Because natal-
izumab blocks α4-integrin-dependent lymphocyte entry into
the brain, not the overall cellular immunodeﬁciency but the
failure of the brain’s immune surveillance is considered respon-
sible for the development of PML (Hirsch et al., 2013). JCV
DNA was detected in oligodendrocytes, astrocytes and cere-
bellar granular cell neurons of the brains of humans without
PML. The most common site for viral latency was cortical
oligodendrocytes (65% of the samples analyzed). Immuno-
compromised patients more frequently harbored JCV DNA in
cerebellar granular cell neurons than immunocompetent patients
(Bayliss et al., 2012). This indicates that JCV DNA is present
in cells of the human brain without clinical symptoms of PML
and supports the hypothesis that reactivation of latent brain
JCV may be central to disease pathogenesis (Bayliss et al., 2011,
2012).
The obligate intracellular parasite Toxoplasma gondii can infect
and replicate within mammalian or avian cells including those
residing in the brain. Circulating white blood cells, particu-
larly dendritic cells and macrophages, are intracellularly infected
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and allow the parasite to spread hematogeneously to the brain
and muscle (Kamerkar and Davis, 2012). In vitro, approxi-
mately 30% of the microglial cells compared to 10% of neu-
rons and astrocytes were intracellularly infected with T. gondii
(Lüder et al., 1999). In vitro, microglial cells and astrocytes were
able to inhibit parasite replication upon activation (Chao et al.,
1993). Traditionally, latent infections in humans were assumed
to be largely asymptomatic, but recently behavioral abnormal-
ities including schizophrenia have been linked with latent T.
gondii infections (Webster, 2007). In HIV-infected individuals
receiving no effective antiretroviral therapy, cerebral toxoplasmo-
sis became a major complication and an AIDS-deﬁning disease.
When the host’s cerebral immune response weakens, parasite
tissue cysts rupture and release bradyzoites which convert to
rapidly dividing tachyzoites and cause T. encephalitis (Sullivan
et al., 2009).
Statement: few typical pathogens only are able to overcome
the immune defense of the healthy brain (e.g., S. pneumoniae,
N. meningitidis, and H. inﬂuenzae causing acute meningitis and
HSV-1 causing acute encephalitis). Conversely, in the immuno-
compromised host a wide spectrum of pathogens can cause acute,
subacute or chronicCNS infections. The example of T. gondii illus-
trates that latent, principally well-controlled CNS infections even
in immunocompetent hosts may lead to behavioral abnormalities.
RESISTANCE OF THE HEALTHY BRAIN AGAINST INFECTIONS
The resistance of the brain to infections can be studied by direct
injection of rapidly multiplying pathogens in a small volume
into the brain parenchyma. With this experimental approach, the
immune response in the ﬁrst hours determines whether the host
organism survives or eventually succumbs to an infection. Since
circulating leukocytes generally need several hours to migrate into
the central nervous compartments (Ernst et al., 1983), the ability of
the host to eliminate invaded pathogens in the ﬁrst hours depends
on the local immune defense, i.e., the activity of microglial cells.
For a variety of highly virulent pathogens, the healthy brain
possesses a remarkable resistance to infection, e.g., the brain of
an immunocompetent young mouse can clear up to 3 × 107
colony-forming units (CFU) of Staphylococcus aureus injected
into the forebrain without developing brain abscess or meningitis
(Figure 1). To overcome the local defense of the mouse against
this pathogen and reliably produce brain abscesses in experimen-
tal conditions, S. aureus had to be embedded into agarose beads
(Kielian and Hickey, 2000).
Even when S. pneumoniae, the most frequent agent causing
community-acquired bacterial meningitis, is injected into the
murine neocortex in a low number, depending on the injected
inoculum and the mouse strain used some animals are capable to
overcome the infection without development of meningitis. The
inoculum size necessary to induce lethal meningitis with E. coli, a
pathogen predominantly causing meningitis in newborns, infants,
old, or immunosuppressed people, lies between the inocula neces-
sary to induce S. pneumoniae and S. aureus meningoencephalitis
(Figures 2 and 3).
Although white blood cells are not at the site of intracerebral
infection in the ﬁrst hours, granulocytopenia leads to a strong
increase of the susceptibility of mice to an intracerebral injectionof
FIGURE 1 | Bacterial concentrations of Staphylococcus aureus
AmericanType Culture Collection (ATCC) 29213 in cerebellar
homogenates (n = 4 animals per inoculum) 168 h after intracerebral
infection with different inocula of S. aureus under anesthesia.
Horizontal bars indicate median values, the detection limit was 10
colony-forming units (CFU)/ml (Marija Djukic, unpublished data). Please
note that all mice were able to clear an inoculum of 3 × 107 bacteria within
1 week.
S. pneumoniae orE. coli (Figures 2 and 3). This observation under-
lines the importance of the cross-talk between resident immune
cells, the vascular endothelium and circulating leukocytes (Perry
et al., 2003) for the proper functioning of microglial cells. In exper-
imental septicaemia-induced S. pneumoniae meningitis,microglia
appeared to sense bacterial adhesion to the endothelial cells and
were activated immediately, before meningitis developed (Iovino
et al., 2013).
Microglia as part of the mammalian innate immune sys-
tem express germ line-encoded pattern recognition receptors
(PRRs) that are crucial in the recognition of pathogens. Toll-like
receptors (TLRs), RIG-like receptors (RLRs), and nucleotide-
binding oligomerization domain-leucine rich repeat containing
(NLR) proteins serve as PRRs that recognize different micro-
bial structures, so-called pathogen-associated molecular patterns
(PAMPs). TLR signaling and the resulting transcriptional acti-
vation of immune response genes requires the adaptor molecule
myeloid differentiation factor 88 (MyD88), except for TLR3 sig-
naling. Intact TLR → MyD88 signaling was essential for the
survival in the acute phase of infection and for control of bac-
terial replication in both intracerebrally inoculated E. coli K1
(Ribes et al., 2013) and intracisternally injected S. pneumoniae
(Koedel et al., 2004). In our experience, Myd88−/− mice rapidly
succumbed to E. coli meningoencephalitis even at a very low
inoculum size (Figure 3). After oral infection with T. gondii,
MyD88 was essential in establishing the protective host response
in the CNS (Torres et al., 2013). T. gondii, an intracellular pro-
tozoan parasite, establishes a latent chronic infection primarily
in the brain after replication of the parasite (tachyzoite form)
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FIGURE 2 | Kaplan–Meier survival curves after intracerebral injection
of different numbers of Streptococcus pneumoniae D39 (kindly
provided by Prof. Dr. Sven Hammerschmidt, University of Greifswald,
Germany). (A) C57Bl/6 immunocompetent mice, (B) C57Bl/6 mice
rendered neutropenic with 50 μg of an anti-Ly-6G monoclonal antibody
(1A8 clone). Meningitis was induced by bacterial inoculation into the right
frontal neocortex under anesthesia. Please note that 70% of
immunocompetent mice survived an intracerebral injection of 200
colony-forming units (CFU). Conversely, all neutropenic mice were killed by
an intracerebral inoculum of 100 CFU in less than 3 days suggesting that
microglia need the cross-talk with granulocytes across the blood–brain
barrier to function properly (Sandra Ribes, unpublished data).
in various organs during the acute stage of infection. While
other organs (e.g., liver, lungs, heart, and small intestine) were
not affected, in Myd88−/− mice mortality was caused by severe
toxoplasmic encephalitis which correlated with low numbers of
CD8+ T cells and a signiﬁcantly higher inﬁltration of the brain
with CD11b+ and F4/80+ cells compared to Myd88+/+ con-
trol mice (Torres et al., 2013). F4/80+ cells were together with
CD11c− and CD11b+ cells responsible for parasite dissemi-
nation to the brain (Courret et al., 2006; Torres et al., 2013).
Macrophage/microglial activation was observed all over different
brain regions of T. gondii-infected Myd88−/−, and only deﬁ-
cient mice showed numerous clusters of ameoboid microglial cells
(Torres et al., 2013).
TLR3 is a sensor for viral double-stranded RNA (dsRNA)
which signals through the Toll–interleukin-1 (IL-1) receptor
(TIR)-domain-containing adaptor inducing IFN-β (TRIF).A pro-
tective role of the TLR3-TRIF-mediated pathway was reported in
FIGURE 3 | Kaplan–Meier survival curves from (A) C57Bl/6J wild-type
(wt) mice and (B) C57Bl/6J MyD88−/− mice following intracerebral
injection of different numbers of Escherichia coli K1 (kindly provided
by Dr. Gregor Zysk, Düsseldorf). Meningitis was induced by bacterial
inoculation into the right frontal neocortex under anesthesia. Please note
that 70% of immunocompetent mice survived an intracerebral injection of
3500 colony-forming units (CFU). Conversely, over 90% of MyD88−/−
mice were killed by an intracerebral inoculum of 150 CFU in less than
4 days suggesting that MyD88 as a central signaling molecule of the innate
immune system is essential for the inactivation of bacteria by parenchymal
microglia and macrophages (Sandra Ribes, unpublished data).
response to Poliovirus (PV), the causative agent of poliomyelitis
(Abe et al., 2012). TLR3 and TRIF signaling pathways inhibited
PV replication in non-neural tissues thereby inﬂuencing the viral
invasion of the CNS. TRIF-deﬁcient mice (triflps2) were not more
susceptible to intracerebralE. coliK1 infection thanwild-typemice
of the same age and background (Ribes et al., 2013).
Statement: the resistance of the CNS of healthy hosts to infec-
tion as assessed by direct injection of pathogens into the brain
tissue is higher than often perceived. The infection resistance
relies on the ability of microglial cells and resident macrophages
to phagocytose and kill pathogens, which is strengthened by the
cross-talk with circulating immune cells.
MICROGLIA CAN BE STIMULATED TO PHAGOCYTOSE AND
KILL BACTERIA AND FUNGI
In vitro, unstimulated microglia phagocytosed E. coli and S. pneu-
moniae at a low rate. Phagocytosis was stimulated by TLR2, 3,
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4, and 9 agonists and by the nucleotide-binding oligomerization
domain-containing protein 2 (NOD2) agonist muramyl dipep-
tide (Ribes et al., 2009, 2010a,b, 2012). These agents also increased
intracellular bacterial killing. The presence of a bacterial capsule as
one important virulence factor decreased the rate of phagocytosis
of E. coli and S. pneumoniae by one order of magnitude compared
to unencapsulated strains (Ribes et al., 2009, 2010a,b, 2012). Ago-
nists of the innate immune system also enhanced the phagocytosis
of Cryptococcus neoformans (Redlich et al., 2013). The increase
of phagocytosis by stimulation of microglial cells via agonists of
receptors of the innate immune was accompanied by a release of
NO and proinﬂammatory cytokines.
Phagocytosis of Mycobacterium tuberculosis by microglial cells
can be inhibited by antibodies against CD14, which together
with TLR4 forms the LPS receptor (Peterson et al., 1995).
Microglial cells also can phagocytose the predominantly intra-
cellular pathogen L. monocytogenes. After bacterial ingestion,
microglia appeared to act as Trojan horses, transporting and
releasing the phagocytosed bacteria inside the brain tissue after
systemic infection (Serbina et al., 2008; Remuzgo-Martínez et al.,
2013). To our knowledge, intracellular killing of mycobacteria
and L. monocytogenes by microglial cells has not been studied.
Among human monocytes, two subsets indistinguishable by the
expression of cell surface markers involved in the phagocytosis
of microbes were observed: approximately 75% of all mono-
cytes were not very active in phagocytosing L. monocytogenes, but
restricted intracellular growth. Approximately 25% could ingest
a large number of bacteria and permitted intracellular growth of
L. monocytogenes (Zerlauth et al., 1996). Monocytes which were
able to kill L. monocytogenes, secreted more TNFα than those
who allowed intracellular replication of bacteria (Zerlauth et al.,
1996). In vitro, microglias were able to phagocytose and inhibit the
growth of T. gondii in a NO-dependent manner, which was stim-
ulated by IFNγ and LPS. In contrast to microglial cells, uptake
of T. gondii into astrocytes was parasite-driven, and astrocytes
were unable to inhibitmultiplication of tachyzoites suggesting that
astrocytes may provide a safe harbor for T. gondii (Peterson et al.,
1993).
For the phagocytosis and intracellular killing of many
pathogens, data on microglial cells are incomplete. The contribu-
tion of monocytes to the control of other pathogens able to cause
CNS infections including fungi is compiled in a recent review
(Serbina et al., 2008).
In E. coli experimental meningitis, pre-treatment with the
TLR9 agonist cytosine-guanine oligodeoxynucleotide 1668 (CpG)
strongly increased survival of neutropenic C57Bl6 mice. The
protective effect was associated with long-term increased lev-
els of IL-12/IL-23p40 in serum and spleen. CpG-treated neu-
tropenic mice had reduced bacterial concentrations in brain
and spleen 42 h after infection (Ribes et al., 2014). Although
the administration of CpG caused sickness behavior and the
release of proinﬂammatory cytokines, no long-term neurologi-
cal abnormalities were noted in surviving CpG-treated mice. This
work indicates that systemic immunostimulation with a TLR9
agonist can not only protect against systemic bacterial infec-
tions but also against an intracerebral bacterial challenge (Ribes
et al., 2014). In microglial-neuronal co-cultures, stimulation
of microglia by Pam3CSK4 (TLR2), LPS (TLR4), and CpG
(TLR9) caused injury to the neurons starting at the axons (Iliev
et al., 2004; Schütze et al., 2012). Therefore, the approach may
entail the risk of inducing collateral damage to the nervous
tissue.
Statement: microglia can be stimulated by a variety of com-
pounds to phagocytose and kill pathogens in vitro. Preliminary
data suggest that systemic administration of these compounds
can also increase the resistance of the brain to infections. This
approach, however, may entail the risk of inducing collateral
damage to the nervous tissue
MICROGLIAL CYTO- AND CHEMOKINE RELEASE DEPENDS
ON THE PROINFLAMMATORY STIMULUS AND THE SUBSET
OF MICROGLIAL CELLS ACTIVATED
The microglial response upon contact with products of infec-
tious agents or synthetic analogs of them is not uniform: in
primary microglial cultures from newborn mice, incubation of
microglia with agonists of the TLR2 (0.1 μg/ml Pam3CSK4), TLR4
(0.01 μg/ml LPS), and TLR9 (1 μg/ml CpG) at the lowest con-
centrations inducing maximum NO release caused a comparable
release of TNFα (Ribes et al., 2009). In vitro and in vivo, how-
ever, synthesis of TNFα is not a common feature of all microglia,
but restricted to a speciﬁc subset. The proportion of TNFα-
producing microglia increased from approx. 30% in neonatal to
75% in young adult microglial cells (Scheffel et al., 2012; Hanisch,
2013). The synthesis of CCL3 (macrophage inﬂammatory pro-
tein 1α, MIP-1α) was restricted to a rather small subpopulation,
and most of the CCL3-synthesizing cells belonged to the (larger)
population of TNFα producers (Scheffel et al., 2012; Hanisch,
2013).
Unlike TNFα, stimulation of microglia with the same TLR
agonists at equal potencies resulted in a divergent release of
CXCL1. Pam3CSK4 at 0.1 μg/ml was the stimulus that induced
higher CXCL1 concentrations in the cell culture supernatants
compared to 0.01 μg/ml LPS and 1 μg/ml CpG (Ribes et al.,
2009). While stimulation with the TLR2 agonist Pam3CSK4 led
to a predominant release of IL6, incubation with the TLR4 lig-
and LPS produced the highest levels of CCL5 (RANTES) (Ribes
et al., 2010b). The subset distribution of the cells releasing these
cyto- and chemokines remains to be determined. Our data, how-
ever, demonstrate that microglial cells do not respond uniformly
to infectious stimuli, but are able to mount a nuanced reaction.
Human innate immune cells stimulated by TLR agonists selec-
tive for TLR7 or TLR8 also did not react in a uniform way: TLR7
agonists directly activated plasmacytoid dendritic cells and, to a
lesser extent, monocytes. On the contrary, TLR8 agonists directly
activated myeloid dendritic cells, monocytes, and monocyte-
derived dendritic cells. TLR7-selective agonists were more potent
than TLR8-selective agonists at inducing IFN-inducible protein
and IFN-inducible T cell alpha chemoattractant from human
mononuclear cells. Conversely, TLR8 ligands were more effective
than TLR7 agonists at inducing TNFα, IL-12 and MIP-1α (Gorden
et al., 2005). In microglia, the TLR4 co-receptor CD14 played an
important role in controlling the proﬁles of cyto/chemokine pro-
duction. Dependent on the TLR4 agonist (different classes of LPS,
ﬁbronectin) and the activation of co-receptors, distinct signaling
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routes are activated leading to a modulation of response proﬁles of
key cytokines (Regen et al., 2011). Hence, for the immune response
of microglial cells it also appears of importance which TLR and
which co-receptor(s) are stimulated.
Statement: unlike previously thought, an accumulating body of
evidence demonstrates the diversity of microglial cells. This opens
avenue to selectively stimulate sub-populations responsible for the
defence against pathogens without stimulating sub-populations
which are responsible for collateral damage to the nervous tissue.
THE EFFICIENCY OF MICROGLIA TO PREVENT CNS
INFECTIONS DEPENDS ON CO-OPERATION WITH
CIRCULATING IMMUNE CELLS
Microglia and CNS macrophages cross-talk with circulating blood
cells by several mechanisms (Perry et al., 2003): (a) the bi-
directional passage of circulating cytokines or pro-inﬂammatory
pathogen compounds through leaks of the blood–brain barrier
(physiologically in the circumventricular organs, under patho-
logical conditions at lesion sites with an impaired blood–brain
barrier), (b) the activation of endothelial cells and perivascular
macrophages either by circulating or brain-derived compounds,
(c) via the vagus nerve. CD11b+Ly-6G+Ly-6Cint granulocytes
and CD11b+Ly-6G−Ly-6Chigh monocytes in the bloodstream
were required for the control of intracerebrally injected E. coli
K1 (Ribes et al., 2013). Animals that received intraperitoneally
an anti-Gr-1 antibody (clone RB6-8C5) showed an earlier and
higher mortality than anti-IgG2b-treated mice (92.3 vs. 11.1%,
P = 0.0002). Depletion of CD11b+Ly-6G+Ly-6Cint granulocytes
from the systemic circulation by intraperitoneal injection of the
anti-Ly-6G antibody (clone 1A8) also had an inﬂuence on the sur-
vival of E. coli K1 infected mice (mortality 59.2% compared to
34.6% in anti-IgG2a-treated animals, P = 0.049). We hypothesize
that after intracerebral bacterial infection the primary immune
response determines whether the infected organism will survive
without antibiotic treatment or will eventually succumb to the
infection. This is supported by the course of the clinical score in
mice. All animals which develop serious symptoms of infection
eventually die, unless they are treated with antibiotics. Animals
which eventually survive either show no signs of infection or
are mildly lethargic in the ﬁrst hours after infection and then
recover. Immediately after inoculation of bacteria, before bac-
teria start to multiply, resident phagocytes as the primary line of
defence have the opportunity to phagocytose and kill the inocu-
lum. Data from experimental S. pneumoniae meningitis models
suggest that after bacterial inoculation granulocytes need approx.
12 h (e.g., Ernst et al., 1983) to migrate into the CSF, i.e., in the
ﬁrst hours after infection the resident phagocytes are on their own.
When the inoculum is high enough to overcome the primary
immune defence of resident phagocytes, invading granulocytes
are not able to control multiplication of bacteria in the intracra-
nial compartments. Granulocyte invasion therefore represents a
futile secondary immune response in this condition. In the CSF
of rabbits rendered leukopenic by nitrogen mustard, the growth
rate of S. pneumoniae was slightly increased (mean generation
time 60 vs. 67 min), and ultimate bacterial density in the CSF was
slightly higher than in immunocompetent rabbits, i.e., leukocytes
did not effectively slow or limit the growth of pneumococci in
the CSF in vivo (Ernst et al., 1983). For these reasons, the strong
detrimental effect of neutropenia on the resistance of the brain
to intracerebral E. coli infection was unexpected and can be only
explained by the cross-talk of resident phagocytes and circulating
leukocytes across the blood–brain and blood–CSF barrier (Ribes
et al., 2013).
Statement: the protective action of microglia against infections
critically depends on the cross-talk with circulating granulocytes
and monocytes in the ﬁrst hours, before circulating leukocytes
enter the brain and CSF. For this reason, immunosuppressive
measures affecting all or speciﬁc subsets of circulating leukocytes
probably bear the risk of also affecting microglial function by
impairing this cross-talk.
PHAGOCYTOSIS AND KILLING OF PATHOGENS BY
MICROGLIA DOES NOT NECESSARILY REQUIRE NITRIC
OXIDE OR CYTOKINE RELEASE
Bacterial clearance by phagocytes of the central nervous com-
partments apparently does not always require the presence of
interferonγ (IFNγ) and nitric oxide (NO): in experimental
S. pneumoniae meningitis, IFNγ−/− mice showed reduced gene
expressionof NOsynthase, but bacterial clearancewas enhanced in
IFNγ−/− compared to wild-type infected animals (Mitchell et al.,
2012). In vitro, the addition of 100 U/ml IFNγ did not increase the
uptake of an unencapsulated strain of E. coli by TLR4-stimulated
microglia while it moderately increased the bacterial ingestion by
TLR2- and TLR9-stimulated cells (Figure 4). In microglial cul-
tures pre-stimulated with different agonists of the innate immune
system, NO release and phagocytosis of bacteria do not strongly
correlate (Ribes et al., 2012; Figure 5).
At present, it is unclear whether all microglial cells or only a
fraction of them is involved in the phagocytosis and inactivation
of pathogens. Myelin uptake under pathophysiological condi-
tions apparently is executed by a fraction of microglia (Scheffel
et al., 2012; Hanisch, 2013). For this reason, it is probable that
a subgroup of microglial cells bears phagocytic activity against
pathogens (Hanisch, 2013). Selective stimulation of the activity of
the subgroup(s) of microglial cells, which phagocytose pathogens,
appears a feasible goal of future research.
Statement: since NO release probably is a main cause of col-
lateral damage to nervous tissue after microglial activation, the
ﬁnding that elimination of pathogens does not necessarily depend
on NO release encourages the search for stimulants which increase
pathogen clearance without inducing damage to the nervous
tissue.
ANTIBIOTIC TREATMENT: REDUCING THE RELEASE OF
PROINFLAMMATORY COMPOUNDS OF PATHOGENS IN
ORDER TO PREVENT EXCESSIVE MICROGLIAL ACTIVATION
Injury and mortality of bacterial meningitis is caused by the joint
action of multiplying bacteria and released bacterial products,
the local immune response of the brain and by granulocytes and
monocytes invading the subarachnoid space and nervous tissue
from the blood (Nau and Brück, 2002; Mook-Kanamori et al.,
2011; Nau et al., 2013).The contribution of these individual mech-
anisms depends on the pathogen and the host’s immune response.
Microglial cells stimulated by bacterial products can kill neurons
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FIGURE 4 | Effect of interferonγ (IFNγ) on bacterial phagocytosis by
Toll-like receptor-stimulated primary microglia. (A) 30 min and (B)
90 min of phagocytosis of E. coli DH5α by microglial cells after 24 h of
stimulation with theTLR agonists: 0.1 μg/ml Pam3CSK4 (P3C), 0.01 μg/ml
LPS and 1 μg/ml CpG alone or in combination with 100 U/ml IFNγ. After
stimulation, cells were washed and bacteria were added for different time
periods (30 and 90 min). Then, gentamicin (200 μg/ml) was added for 1 h to
kill extracellular bacteria. Thereafter, bacteria were lysed in 0.1 ml of
distilled water. The number of ingested bacteria was determined by
quantitative plating of the cell lysates after the different incubation
intervals. Data are shown as recovered bacteria (CFU) per well
[mean ± SEM (error bars)]. Data were analyzed using one-way ANOVA
followed by Bonferroni’s multiple comparison test (#P < 0.05; ##P < 0.01;
Sandra Ribes, unpublished data).
in vitro (Iliev et al., 2004). Reduction of the amount of proinﬂam-
matory/toxic pathogen-derived products avoids overstimulation
of resident and migrating immune cells including microglia and
thereby protects the nervous tissue. For this reason, it appears
desirable to keep the concentrations of proinﬂammatory products
of pathogens in the central nervous tissue low during the whole
course of an infection including its treatment. This aspect of
microglial stimulation has been most extensively studied in bacte-
rial meningitis, but probably is of importance also for other CNS
infections, particularly for those with a high pathogen load.
In clinical practice, a favorable outcome depends on rapid
antibiotic treatment after hospital admission (Auburtin et al.,
2006). Although many antibiotics commonly used in the manage-
ment of bacterial meningitis cause bacterial lysis and subsequent
release of proinﬂammatory or directly cytotoxic compounds,
rapid antibiotic treatment stops bacterial replication and pro-
duction of bacterial products and therefore on the long run
reduces the concentrations of proinﬂammatory/toxic bacterial
products in the CNS (Stuertz et al., 1998; Spreer et al., 2003).
In vitro, temporarily the pneumolysin release was higher in
ceftriaxone-treated S. pneumoniae compared to untreated S. pneu-
moniae cultures. After 3 h, however, the pneumolysin release
during spontaneous growth exceeded the release after initiation
of ceftriaxone treatment. In particular, a strong increase of extra-
cellular pneumolysin was observed when untreated pneumococci
reached the end of the logarithmic growth phase (Spreer et al.,
2003).
In contrast to the classical view considering bactericidal and
bacteriolytic synonyms, the cidal and the lytic effects of an
antibiotic do not necessarily coincide. With cell-wall active
antibacterials, in particular beta-lactam antibiotics, lytic and
cidal action are tightly linked. Bactericidal antibiotics acting by
the inhibition of RNA or protein synthesis or DNA replication
(rifamycins, macrolides, clindamycin, ketolides, and with some
limitations also quinolones) circumvent or at least delay bac-
terial lysis (for review, see Nau and Eiffert, 2002, Nau et al.,
2013). In animal models of bacterial meningitis, rifampicin,
clindamycin and daptomycin reduced inﬂammation, mortality,
neuronal injury or/andneurological long-term sequelae compared
to the standard therapy with beta-lactam antibiotics (Nau et al.,
1999; Gerber et al., 2003; Böttcher et al., 2004; Grandgirard et al.,
2007, 2012; Spreer et al., 2009; Barichello et al., 2013; Nau et al.,
2013).
Statement: the reduction of potentially deleterious pathogen-
derived compounds by rapid initiation of an effective antibiotic
therapy or by choosing compounds which do not release large
amounts of pathogen products is a promising strategy to avoid
overstimulation of microglial cells and decrease neuronal injury.
PLEIOTROPIC COMPOUNDS INHIBITING MICROGLIAL
FUNCTION
The role of corticosteroids in infections of the CNS has been
debated for decades.
In vitro, dexamethasone inhibited the release of TNFα and
IL-1β by microglia after exposure to LPS (Forshammar et al.,
2013). After dexamethasone exposure, pronounced transcrip-
tional effects were observed in microglia, where 257 genes
were differentially expressed. The majority of these genes were
related to the immune function (Jenkins et al., 2013). Con-
versely, corticosteroids can delay the production of myelin.
In high-purity cell cultures, however, oligodendrocyte lin-
eage cells were not inﬂuenced by exposure to dexamethasone.
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FIGURE 5 | Microglial NO release and phagocytosis of bacteria.
(A) Stimulation with TLR2 or 4 agonists induced stronger microglial nitric
oxide (NO) release than stimulation with a TLR3 agonist or muramyl
dipeptide (MDP). Dose–response relations after 24 h treatment with
various concentrations of agonists of TLR1/2 (Pam3CSK4), TLR3
[poly(I:C)], TLR4 (LPS), and NOD2 (MDP; Ebert et al., 2005; Ribes et al.,
2009; Ribes et al., 2012). (B) Phagocytosis of E. coli K1 strain by
microglial cells after 24 h of stimulation with the agonists at the lowest
concentration inducing maximum NO release: 0.1 μg/ml Pam3CSK4,
10 μg/ml poly(I:C), 0.01 μg/ml LPS, and 10 μg/ml MDP (means ± SD,
∗∗∗p < 0.001 vs. medium-treated cells); Student’s t test and correction
for repeated testing by the Bonferroni–Holm method. Please note that
although stimulation with poly(I:C) and MDP released low amounts of
NO, both compounds led to a substantial increase of bacterial
phagocytosis (Figure reproduced from Ribes et al., 2012, with permission
of the publisher).
Untreated microglial cell cultures showed a branching rami-
ﬁed morphology indicative of the “resting” state. Dexametha-
sone exposure dramatically reduced cell densities, and thereafter
many cells showed a rounded appearance. Corticosteroid-treated
microglia may demonstrate an impaired ability to migrate toward
and phagocytose cells/synapses and myelin debris and proba-
bly thereby indirectly affects myelination (Jenkins et al., 2013).
Whether corticosteroids also inhibit phagocytosis and intracel-
lular inactivation of pathogens by microglia, remains to be
studied.
Dexamethasone as an adjunct to antibiotic treatment in the
adult rabbit model of S. pneumoniae and in the infant rat
models of Streptococcus group B and S. pneumoniae menin-
gitis aggravated apoptotic neuronal injury in the hippocam-
pal dentate gyrus and impaired long-term learning capacity
of surviving rats in the Morris water maze compared to rats
treated with an antibiotic only (Leib et al., 1996, 2003; Zysk
et al., 1996; Spreer et al., 2006; Nau et al., 2013). There is,
however, no evidence of an aggravation of human hippocam-
pal injury in bacterial meningitis by adjunctive dexamethasone
(Brouwer et al., 2013; Nau et al., 2013). Data from clinical tri-
als at present point to a beneﬁcial effect of corticosteroids as
an adjunct to antibiotic therapy in community-acquired acute
bacterial and Tuberculous meningitis (Thwaites et al., 2009;
Brouwer et al., 2013). In other CNS infections (e.g., cerebral
toxoplasmosis, brain abscess, HSV encephalitis), glucocorticoids
should be used only in the presence of a life-threatening brain
edema.
Cytostatics such as mitoxantrone and cyclophosphamide and
the antimetabolites methotrexate and azathioprine act on a vari-
ety of proliferating cells and as immunosuppressants probably also
inhibit proliferation and function of microglial cells (e.g., Vairano
et al., 2004; Li et al., 2012). New agents used for the treatment of
MS also have pleiotropic effects including a direct inﬂuence on
microglial activity. Fingolimod inhibits autoreactive lymphocytes
from inﬁltrating the CNS, but also downregulates the produc-
tion of the pro-inﬂammatory cytokines TNFα, IL-1β, and IL-6 by
activated microglia (Noda et al., 2013).
Statement: the long-term use of pleiotropic compounds affect-
ing microglial function increases the risk of CNS infections.
In community-acquired bacterial meningitis, dexamethasone as
an adjunct to antibiotic treatment at present represents the
standard therapy to inhibit the systemic inﬂammatory and the
local microglial response of the host. Corticosteroids or other
pleiotropic immunosuppressive compounds probably are not the
ideal agents for this purpose, because they affect the ability of
microglia to clear pathogens. This is of particular importance,
when antiinfectives are not able to kill all causative pathogens.
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FIGURE 6 | Activation of microglia byToll-like receptor (TLR) agonists and
by palmitoylethanolamide (PEA).The activation by both ways leads to an
increase of phagocytosis and intracellular killing of pathogens. Stimulation of
one or several TLR or nucleotide-binding oligomerization domain-containing
protein 2 (NOD2) receptors causes the release of proinﬂammatory products
from microglial cells causing neuronal injury in microglial-neuronal co-cultures
and probably also in vivo. PEA also increases phagocytosis and intracellular
killing of pathogens. To our knowledge, it does not release proinﬂammatory
mediators. For this reason we hypothesize that it will not cause collateral
neuronal injury. PEA probably acts via the peroxisome proliferator-activated
receptor (PPAR)α, but also is a ligand of the transient receptor potential
vanilloid-1 (TRPV1) and the orphan G-protein coupled receptor GPR55 (De
Petrocellis et al., 2001; LoVerme et al., 2005, 2006; Ryberg et al., 2007;
Esposito and Cuzzocrea, 2013).
COMPOUNDS STIMULATING PHAGOCYTOSIS BY
MICROGLIAL CELLS WITHOUT INDUCING AN
INFLAMMATORY REACTION
Palmitoylethanolamide (PEA) is a small endogenous lipid (molec-
ular mass 299.5 g/mol) which is widely present in cells including
microglia (Muccioli and Stella, 2008), tissues and body ﬂuids. It
has analgesic, anticonvulsant, neuroprotective, antipyretic and
anti-inﬂammatory properties. Its actions depend mainly on the
peroxisome proliferator-activated receptor (PPAR)α, but it also is
a ligand of the transient receptor potential vanilloid-1 (TRPV1)
and the orphan G-protein coupled receptor GPR55 (De Petro-
cellis et al., 2001; LoVerme et al., 2005, 2006; Ryberg et al., 2007;
Esposito and Cuzzocrea, 2013). In a murine Theiler’s virus model
of chronic MS, treatment with PEA (5 mg/kg) between days 60
and 70 post-infection resulted in a strong improvement of motor
deﬁcits caused by a reduction of microglial activation observed in
untreated mice (Loría et al., 2008).
In spite of its anti-inﬂammatory properties, 30 min pre-
treatment with PEA stimulated phagocytosis of S. pneumoniae
(EC50 5.9 nM) and E. coli (EC50 23 nM) by microglial cells in
vitro. It was not toxic to microglial cells up to a concentration of
1000 nM. Unlike pre-stimulation with TLR and NOD2 agonists,
the PEA-mediated increase of microglial bacterial uptake was not
accompanied by a release of pro-inﬂammatory cyto-/chemokines
[TNFα, IL-6, and CXCL1 (KC)], avoiding the risk of concomi-
tant neuronal injury (Redlich et al., 2012). Preliminary data
suggest that PEA also decreases the susceptibility of the brain
to intracerebral injection of bacteria (Sandra Redlich, unpub-
lished data). From 1969 to 1979, PEA was tested under the brand
name ImpulsinR (SPOFA United Pharmaceutical Works, Prague,
Czechoslovakia) in prophylactic and therapeutic clinical trials (ﬁve
in adults, one in children): it reduced the incidence and sever-
ity of acute respiratory infections and inﬂuenza (Kahlich et al.,
1979; Keppel Hesselink et al., 2013). More than 3600 patients
received PEA at daily doses from 600 to 1800 mg, and no severe
adverse effects were reported (Kahlich et al., 1979; Keppel Hes-
selink et al., 2013).These properties illustrate that PEA is a true
immunomodulator and not an immunosuppressant and make
PEA a promising agent to enhance the resistance of the brain
against infection without carrying the risk of inducing neuronal
injury (Figure 6). This effect may be of clinical value both in
preventing bacterial CNS infections in high-risk groups and in
reducing the invasion of pathogens into brain tissue in manifest
meningeal infections.
Glatiramer acetate also increased phagocytosis in vitro (Pul
et al., 2011, 2012): the ingestion of ﬂuorescent beads was greater in
monocytes from MS patients treated with glatiramer acetate than
in those from healthy controls or non-treated MS patients. Only
monocytes co-expressing CD16 were observed to phagocytose,
and addition of IL-10 did not decrease phagocytosis (Pul et al.,
2012). Moreover, in primary rat microglia glatiramer acetate pro-
moted the phagocytosis of ﬂuorescent latex beads and increased
IL-10 secretion, whereas it decreased the release of TNFα and did
not affect NO release (Pul et al., 2011). Phagocytosis of bacteria,
however, was not studied. Glatiramer acetate, a random polymer
of four amino acids found in myelin basic protein (glutamic acid,
lysine, alanine, tyrosine) as a relatively large hydrophilic com-
pound (molecular mass approx. 600 g/mol) in contrast to PEA
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probably crosses the blood–brain andblood–CSFbarrier to a small
extent only. It remains to be studied,whether the glatiramer acetate
CNS concentrations are high enough to inﬂuence the phagocytic
activity of microglia.
Dimethyl fumarate is a small lipophilic compound (molec-
ular mass 144.1 g/mol). Treatment of HIV-infected human
monocyte-derived macrophages with dimethyl fumarate atten-
uated HIV replication in a dose-dependent manner, as deter-
mined by reverse transcriptase concentrations in the culture
supernatants. Dimethyl fumarate also inhibited NF-κB translo-
cation and the release of TNFα from phytohemagglutinin-
activated macrophages and reduced HIV-induced TNFα release
from macrophages (Cross et al., 2011; Gill and Kolson, 2013).
Dimethyl fumarate together with other esters of fumaric acid
has been marketed for several years as an antipsoriasis drug.
Lymphocytopenia and eosinophilia are frequent side effects,
and the compound appears to increase the risk of PML,
Kaposi sarcoma and nocardiosis (manufacturer’s information,
http://www.akdae.de/Arzneimittelsicherheit/RHB/20130625.pdf).
Statement: the data obtained with PEA and, with limitations,
glatiramer acetate anddimethyl fumarate underline that the search
for modulators instead of inhibitors of microglial activity appears
promising.
CONCLUSION
Phagocytosis of pathogens by microglial cells can be stimu-
lated by agonists of receptors of the innate immune system.
The use of this signaling pathway to increase the resistance of
the brain against infections entails the risk of inducing col-
lateral damage to the nervous tissue. As a consequence of
microglial diversity, it appears possible to identify compounds
that increase pathogen uptake and elimination and thereby may
contribute to the protection of the brain without a concomi-
tant measurable proinﬂammatory effect. In this context, PEA,
an endogenous lipid which had been tested clinically in the
1970s and apparently decreased the incidence of respiratory infec-
tions without severe side effects, appears to be most promising.
Based on in-vitro data, glatiramer acetate and dimethyl fumarate
both used for the treatment of MS appear as other potential
candidates.
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